Multidrug-resistant gram-negative bacteria infections in solid organ transplantation

American Journal of Transplantation

Volumn 13, Issue SUPPL.4, 2013, Pages 31-41

  Van Duin, D ^a   Van Delden, C ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Antibiotic resistance; bacterial infection; multidrug resistance; posttransplant infection

Indexed keywords

ACHROMOBACTER; ACINETOBACTER; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ARTICLE; BURKHOLDERIA; BURKHOLDERIA INFECTION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; GRAFT RECIPIENT; GRAM NEGATIVE INFECTION; HUMAN; INFECTION PREVENTION; LUNG TRANSPLANTATION; MULTIDRUG RESISTANCE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PSEUDOMONAS; PSEUDOMONAS INFECTION; RISK FACTOR; SOLID ORGAN TRANSPLANTATION; STENOTROPHOMONAS;

DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; ORGAN TRANSPLANTATION; RISK FACTORS;

EID: 84874874799     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12096     Document Type: Article

References (108)

1. van Duijn PJ, Dautzenberg MJ, Oostdijk EA,. Recent trends in antibiotic resistance in European ICUs. Curr Opin Crit Care 2011; 17: 658-665.
2. Prabaker K, Weinstein RA,. Trends in antimicrobial resistance in intensive care units in the United States. Curr Opin Crit Care 2011; 17: 472-479.
3. Al-Hasan MN, Razonable RR, Eckel-Passow JE, Baddour LM,. Incidence rate and outcome of Gram-negative bloodstream infection in solid organ transplant recipients. Am J Transplant 2009; 9: 835-843.
4. Linares L, Garcia-Goez JF, Cervera C, et al. Early bacteremia after solid organ transplantation. Transplant Proc 2009; 41: 2262-2264.
5. Husain S, Chan KM, Palmer SM, et al. Bacteremia in lung transplant recipients in the current era. Am J Transplant 2006; 6 (12): 3000-3007.
6. Singh N, Gayowski T, Rihs JD, Wagener MM, Marino IR,. Evolving trends in multiple-antibiotic-resistant bacteria in liver transplant recipients: A longitudinal study of antimicrobial susceptibility patterns. Liver Transpl 2001; 7: 22-26.
7. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-281.
8. Moreno A, Cervera C, Gavalda J, et al. Bloodstream infections among transplant recipients: Results of a nationwide surveillance in Spain. Am J Transplant 2007; 7: 2579-2586.
9. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y,. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008; 52: 1028-1033.
10. Shi SH, Kong HS, Jia CK, et al. Risk factors for pneumonia caused by multidrug-resistant Gram-negative bacilli among liver recipients. Clin Transplant 2010; 24: 758-765.
11. Shi SH, Kong HS, Xu J, et al. Multidrug resistant gram-negative bacilli as predominant bacteremic pathogens in liver transplant recipients. Transpl Infect Dis 2009; 11: 405-412.
12. Trottier V, Namias N, Pust DG, et al. Outcomes of Acinetobacter baumannii infection in critically ill surgical patients. Surg Infect (Larchmt) 2007; 8: 437-443.
13. Linares L, Cervera C, Cofan F, et al. Risk factors for infection with extended-spectrum and AmpC beta-lactamase-producing gram-negative rods in renal transplantation. Am J Transplant 2008; 8: 1000-1005.
14. Bellier C, Bert F, Durand F, et al. Risk factors for Enterobacteriaceae bacteremia after liver transplantation. Transpl Int 2008; 21 (8): 755-763.
15. Pinheiro HS, Mituiassu AM, Carminatti M, Braga AM, Bastos MG,. Urinary tract infection caused by extended-spectrum beta-lactamase-producing bacteria in kidney transplant patients. Transplant Proc 2010; 42: 486-487.
16. Kalpoe JS, Sonnenberg E, Factor SH, et al. Mortality associated with carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transpl 2012; 18: 468-474.
17. Bergamasco MD, Barroso Barbosa M, de Oliveira Garcia D, et al. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation. Transpl Infect Dis 2011; 14: 198-205.
18. Reddy P, Zembower TR, Ison MG, Baker TA, Stosor V,. Carbapenem-resistant Acinetobacter baumannii infections after organ transplantation. Transpl Infect Dis 2010; 12: 87-93.
19. Botha P, Archer L, Anderson RL, et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation 2008; 85: 771-774.
20. Hadjiliadis D, Steele MP, Chaparro C, et al. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J Heart Lung Transplant 2007; 26: 834-838.
21. Dobbin C, Maley M, Harkness J, et al. The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: Results from a single large referral centre. J Hosp Infect 2004; 56: 277-282.
22. Aguilar-Guisado M, Givalda J, Ussetti P, et al. Pneumonia after lung transplantation in the RESITRA Cohort: A multicenter prospective study. Am J Transplant 2007; 7: 1989-1996.
23. Meachery G, De Soyza A, Nicholson A, et al. Outcomes of lung transplantation for cystic fibrosis in a large UK cohort. Thorax 2008; 63: 725-731.
24. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 745-755.
25. Gottlieb J, Mattner F, Weissbrodt H, et al. Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis. Respir Med 2009; 103: 743-749.
26. Murray S, Charbeneau J, Marshall BC, LiPuma JJ,. Impact of burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med 2008; 178: 363-371.
27. Boussaud V, Guillemain R, Grenet D, et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: Results from two French centres. Thorax 2008; 63: 732-737.
28. Vandamme P, Dawyndt P,. Classification and identification of the Burkholderia cepacia complex: Past, present and future. Syst Appl Microbiol 2011; 34: 87-95.
29. Alexander BD, Petzold EW, Reller LB, et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant 2008; 8: 1025-1030.
30. Olland A, Falcoz PE, Kessler R, Massard G,. Should cystic fibrosis patients infected with Burkholderia cepacia complex be listed for lung transplantation? Interact Cardiovasc Thorac Surg 2011; 13: 631-634.
31. De Soyza A, Meachery G, Hester KL, et al. Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: A single-center experience. J Heart Lung Transplant 2010; 29: 1395-1404.
32. Nash EF, Coonar A, Kremer R, et al. Survival of Burkholderia cepacia sepsis following lung transplantation in recipients with cystic fibrosis. Transpl Infect Dis 2010; 12: 551-554.
33. Iida T, Kaido T, Yagi S, et al. Posttransplant bacteremia in adult living donor liver transplant recipients. Liver Transpl 2010; 16: 1379-1385.
34. Johnson LE, D'Agata EM, Paterson DL, et al. Pseudomonas aeruginosa bacteremia over a 10-year period: Multidrug resistance and outcomes in transplant recipients. Transpl Infect Dis 2009; 11: 227-234.
35. Hoyo I, Linares L, Cervera C, et al. Epidemiology of pneumonia in kidney transplantation. Transplant Proc 2010; 42: 2938-2940.
36. Vidal E, Torre-Cisneros J, Blanes M, et al. Bacterial urinary tract infection after solid organ transplantation in the RESITRA cohort. Transpl Infect Dis 2012.
37. Linares L, Cervera C, Cofan F, et al. Epidemiology and outcomes of multiple antibiotic-resistant bacterial infection in renal transplantation. Transplant Proc 2007; 39: 2222-2224.
38. Safdar N, Maki DG,. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002; 136: 834-844.
39. Troillet N, Samore MH, Carmeli Y,. Imipenem-resistant Pseudomonas aeruginosa: Risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997; 25: 1094-1098.
40. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP,. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29: 1099-1106.
41. Pop-Vicas A, Mitchell SL, Kandel R, Schreiber R, D'Agata EM,. Multidrug-resistant gram-negative bacteria in a long-term care facility: Prevalence and risk factors. J Am Geriatr Soc 2008; 56: 1276-1280.
42. Perez F, Endimiani A, Ray AJ, et al. Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: Impact of post-acute care facilities on dissemination. J Antimicrob Chemother 2010; 65: 1807-1818.
43. Rooney PJ, O'Leary MC, Loughrey AC, et al. Nursing homes as a reservoir of extended-spectrum beta-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli. J Antimicrob Chemother 2009; 64: 635-641.
44. Linares L, Cervera C, Hoyo I, et al. Klebsiella pneumoniae infection in solid organ transplant recipients: Epidemiology and antibiotic resistance. Transplant Proc 2010; 42: 2941-2943.
45. Martins IS, Moreira BM, Riley LW, Santoro-Lopes G., Outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection among renal transplant recipients. J Hosp Infect 2006; 64: 305-308.
46. Lupei MI, Mann HJ, Beilman GJ, Oancea C, Chipman JG,. Inadequate antibiotic therapy in solid organ transplant recipients is associated with a higher mortality rate. Surg Infect (Larchmt) 2010; 11: 33-39.
47. Rebuck JA, Olsen KM, Fey PD, Langnas AN, Rupp ME,. Characterization of an outbreak due to extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a pediatric intensive care unit transplant population. Clin Infect Dis 2000; 31: 1368-1372.
48. Fernandez J, Acevedo J, Castro M, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: A prospective study. Hepatology 2012; 55: 1551-1561.
49. Fernandez J, Navasa M, Gomez J, et al. Bacterial infections in cirrhosis: Epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35: 140-148.
50. El Amari EB, Chamot E, Auckenthaler R, Pechere JC, Van Delden C., Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 2001; 33: 1859-1864.
51. Reinhardt A, Kohler T, Wood P, et al. Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: A longitudinal observation in mechanically ventilated patients. Antimicrob Agents Chemother 2007; 51: 1341-1350.
52. Saiman L,. Infection prevention and control in cystic fibrosis. Curr Opin Infect Dis 2011; 24: 390-395.
53. Kahlmeter G,. Breakpoints for intravenously used cephalosporins in Enterobacteriaceae-EUCAST and CLSI breakpoints. Clin Microbiol Infect 2008; 14 (Suppl 1): 169-174.
54. Clinical and Laboratory Standards Institute, Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. CLSI document M100-S22 2012; 32.
55. Polsfuss S, Bloemberg GV, Giger J, Meyer V, Hombach M., Comparison of European committee on antimicrobial susceptibility testing (EUCAST) and CLSI screening parameters for the detection of extended-spectrum beta-lactamase production in clinical Enterobacteriaceae isolates. J Antimicrob Chemother 2012; 67: 159-166.
56. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA., Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51: 3471-3484.
57. Zarate MS, Serruto G, Smayevsky J,. The susceptibility to tigecycline of Acinetobacter spp. may vary depending on the methodology used. Int J Infect Dis 2009.
58. Kodaka H, Iwata M, Yumoto S, Kashitani F., Evaluation of a new agar medium containing cetrimide, kanamycin and nalidixic acid for isolation and enhancement of pigment production of Pseudomonas aeruginosa in clinical samples. J Basic Microbiol 2003; 43: 407-413.
59. Cimolai N, Trombley C, Davidson AG, Wong LT., Selective media for isolation of Burkholderia (Pseudomonas) cepacia from the respiratory secretions of patients with cystic fibrosis. J Clin Pathol 1995; 48: 488-490.
60. Pinot C, Deredjian A, Nazaret S, et al. Identification of Stenotrophomonas maltophilia strains isolated from environmental and clinical samples: A rapid and efficient procedure. J Appl Microbiol 2011; 111: 1185-1193.
61. Henry D, Campbell M, McGimpsey C, et al. Comparison of isolation media for recovery of Burkholderia cepacia complex from respiratory secretions of patients with cystic fibrosis. J Clin Microbiol 1999; 37: 1004-1007.
62. Hsieh WS, Sung LL, Tsai KC, Ho HT., Evaluation of the VITEK 2 cards for identification and antimicrobial susceptibility testing of non-glucose- fermenting Gram-negative bacilli. Apmis 2009; 117: 241-247.
63. Aaron SD, Vandemheen KL, Ferris W, et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: A randomised, double-blind, controlled clinical trial. Lancet 2005; 366: 463-471.
64. Sun HY, Shields RK, Cacciarelli TV, Muder RR, Singh N., A novel combination regimen for the treatment of refractory bacteremia due to multidrug-resistant Pseudomonas aeruginosa in a liver transplant recipient. Transpl Infect Dis 2010; 12: 555-560.
65. Chang HJ, Hsu PC, Yang CC, et al. Risk factors and outcomes of carbapenem-nonsusceptible Escherichia coli bacteremia: A matched case-control study. J Microbiol Immunol Infect 2011; 44: 125-130.
66. Zarate MS, Gales AC, Picao RC, Pujol GS, Lanza A, Smayevsky J., Outbreak of OXY-2-producing Klebsiella oxytoca in a renal transplant unit. J Clin Microbiol 2008; 46: 2099-2101.
67. Mathers AJ, Cox HL, Bonatti H, et al. Fatal cross infection by carbapenem-resistant Klebsiella in two liver transplant recipients. Transpl Infect Dis 2009 11: 257-265.
68. Kassis-Chikhani N, Saliba F, Carbonne A, et al. Extended measures for controlling an outbreak of VIM-1 producing imipenem-resistant Klebsiella pneumoniae in a liver transplant centre in France, 2003-2004. Euro Surveill 2010; 15.
69. Paterson DL, Singh N, Rihs JD, Squier C, Rihs BL, Muder RR., Control of an outbreak of infection due to extended-spectrum beta-lactamase-producing Escherichia coli in a liver transplantation unit. Clin Infect Dis 2001; 33: 126-128.
70. Transmission of multidrug-resistant Escherichia coli through kidney transplantation-California and Texas, 2009. Am J Transplant 2011; 11: 628-632.
71. Goldberg E, Bishara J, Lev S, Singer P, Cohen J., Organ transplantation from a donor colonized with a multidrug-resistant organism: A case report. Transpl Infect Dis 2011.
72. Martins N, Martins IS, de Freitas WV, et al. Severe infection in a lung transplant recipient caused by donor-transmitted carbapenem-resistant Acinetobacter baumannii. Transpl Infect Dis 2011.
73. Ariza-Heredia EJ, et al. Outcomes of transplantation using organs from a donor infected with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae. Transpl Infect Dis 2012; 14: 229-236.
74. Bauldoff GS, Nunley DR, Manzetti JD, Dauber JH, Keenan RJ., Use of aerosolized colistin sodium in cystic fibrosis patients awaiting lung transplantation. Transplantation 1997; 64: 748-752.
75. Leung MK, Rachakonda L, Weill D, Hwang PH., Effects of sinus surgery on lung transplantation outcomes in cystic fibrosis. Am J Rhinol 2008; 22: 192-196.
76. Holzmann D, Speich R, Kaufmann T, et al. Effects of sinus surgery in patients with cystic fibrosis after lung transplantation: A 10-year experience. Transplantation 2004; 77: 134-136.
77. Mainz JG, Hentschel J, Schien C, et al. Sinonasal persistence of Pseudomonas aeruginosa after lung transplantation. J Cyst Fibros 2012; 11: 158-161.
78. Orlando G, Di Cocco P, Gravante G, D'Angelo M, Famulari A, Pisani F., Fatal hemorrhage in two renal graft recipients with multi-drug resistant Pseudomonas aeruginosa infection. Transpl Infect Dis 2009; 11: 442-447.
79. Simkins J, Muggia V,. Favorable outcome in a renal transplant recipient with donor-derived infection due to multidrug-resistant Pseudomonas aeruginosa. Transpl Infect Dis 2012; 14: 292-295.
80. Nguyen M, Eschenauer GA, Bryan M, et al. Carbapenem-resistant Klebsiella pneumoniae bacteremia: Factors correlated with clinical and microbiologic outcomes. Diagn Microbiol Infect Dis 2010; 67: 180-184.
81. Pankey GA,. Tigecycline. J Antimicrob Chemother 2005; 56: 470-480.
82. Satlin MJ, Kubin CJ, Blumenthal JS, et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother 2011; 55: 5893-5899.
83. Cai Y, Wang R, Liang B, Bai N, Liu Y., Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011; 55: 1162-1172.
84. Yahav D, Lador A, Paul M, Leibovici L., Efficacy and safety of tigecycline: A systematic review and meta-analysis. J Antimicrob Chemother 2011; 66: 1963-1971.
85. Tasina E, Haidich AB, Kokkali S, Arvanitidou M., Efficacy and safety of tigecycline for the treatment of infectious diseases: A meta-analysis. Lancet Infect Dis 2011; 11: 834-844.
86. Prasad P, Sun J, Danner RL, Natanson C., Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012; 54: 1699-1709.
87. Karageorgopoulos DE, Wang R, Yu XH, Falagas ME., Fosfomycin: Evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother 2012; 67: 255-268.
88. Alexander BT, Marschall J, Tibbetts RJ., Treatment and clinical outcomes of urinary tract infections caused by KPC-producing enterobacteriaceae in a retrospective cohort. Clin Ther 2012; 34: 1314-1323.
89. Daikos GL, Markogiannakis A,. Carbapenemase-producing Klebsiella pneumoniae: (When) might we still consider treating with carbapenems? Clin Microbiol Infect 2011; 17: 1135-1141.
90. Bulik CC, Nicolau DP,. Double-carbapenem therapy for carbapenemase- producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2011; 55: 3002-3004.
91. Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: Superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012; 56: 2108-2113.
92. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by KPC-producing Klebsiella pneumoniae: Importance of combination therapy. Clin Infect Dis 2012. doi: 10.1093/cid/cis588
93. Hirsch EB, Tam VH,. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): An emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010. Epub April 8, 2010.
94. Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011; 17: 1798-1803.
95. Dent LL, Marshall DR, Pratap S, Hulette RB., Multidrug resistant Acinetobacter baumannii: A descriptive study in a city hospital. BMC Infect Dis 2010; 10: 196.
96. Reddy T, Chopra T, Marchaim D, et al. Trends in antimicrobial resistance of Acinetobacter baumannii isolates from a metropolitan Detroit health system. Antimicrob Agents Chemother 2010; 54: 2235-2238.
97. Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E., Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008; 46: 567-570.
98. Shields RK, Kwak EJ, Potoski BA, et al. High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: Using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen. Diagn Microbiol Infect Dis 2011; 70: 246-252.
99. Chamot E, Boffi El, Amari E, Rohner P, Van Delden C., Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2003; 47 (9): 2756-2764.
100. Lim TP, Lee W, Tan TY, et al. Effective antibiotics in combination against extreme drug-resistant Pseudomonas aeruginosa with decreased susceptibility to polymyxin B. PLoS One 2011; 6: e28177.
101. Bergen PJ, Tsuji BT, Bulitta JB, et al. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2011; 55: 5685-5695.
102. Apisarnthanarak A, Mundy LM,. Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: Combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin. Int J Antimicrob Agents 2012; 39: 271-272.
103. Prescott WA, Jr., Gentile AE, Nagel JL, Pettit RS., Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis. P T 2011; 36: 723-763.
104. Arnold HM, Sawyer AM, Kollef MH,. Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia. Respir Care 2012.
105. Naesens R, Vlieghe E, Verbrugghe W, Jorens P, Ieven M., A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa. BMC Infect Dis 2011; 11: 317.
106. Lambiase A, Catania MR, Del Pezzo M, et al. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 2011; 30: 973-980.
107. Brooke JS,. Stenotrophomonas maltophilia: An emerging global opportunistic pathogen. Clin Microbiol Rev 2012; 25: 2-41.
108. Milne KE, Gould IM,. Combination antimicrobial susceptibility testing of multidrug-resistant Stenotrophomonas maltophilia from cystic fibrosis patients. Antimicrob Agents Chemother 2012; 56: 4071-4077.